Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Consensus PT from Analysts

Chronological Source Flow
Back

AI Fusion Summary

Werewolf Therapeutics (NASDAQ: HOWL) has a consensus 12‑month price target of $3.75, with analysts split between hold, buy, and sell. Citigroup downgraded its rating, while HC Wainwright cut its target to $4.00.
#Werewolf Therapeutics #HOWL #price target #analyst ratings #downgrade #Citigroup #HC Wainwright
17/03 07:20 defenseworld.net
3 Πηγές

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Consensus PT from Analysts

Werewolf TherapeuticsHOWLprice targetanalyst ratingsdowngradeCitigroup
17/03 07:36 defenseworld.net

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $4.00 Consensus Price Target from Analysts

CONSENSUS RATING ARTICLESPOLITICSCOMPANIES
17/03 07:37 defenseworld.net

Group 1 Automotive, Inc. (NYSE:GPI) Receives $458.00 Average Target Price from Analysts

POLITICSCOMPANIESCONSENSUS RATING ARTICLESECONOMY
Comments
Loading...
0